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To assess the frequency and perinatal outcomes of gestational diabetes mellitus (GDM)
defined by the criteria according to the International Association of Diabetes in Pregnancy
Study Group (IADPSG) and the National Institute for Health and Care Excellence (NICE)
diagnostic criteria for GDM.
Design
A retrospective cohort study.
Setting
Six secondary and tertiary delivery hospitals in Finland in 2009.
Population
Pregnant women (N = 4,033) and their offspring.
Methods
We used data on comprehensive screening of pregnant women with a 2-h 75-g oral glucose
tolerance test (OGTT), performed between gestational weeks 24 and 40. OGTT glucose
concentrations were used to identify women who fulfilled IADPSG and NICE criteria. While
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cut-offs according to Finnish national criteria partly overlapped with both criteria, a subgroup
of IADPSG- or NICE-positive GDM women remained undiagnosed by Finnish criteria and
hence non-treated. They were analysed as subgroups and compared to controls who were
negative with all cut-offs.
Main outcome measures
GDM prevalence, birth weight SD score (BWSDS), large for gestational age (LGA) and cae-
sarean section (CS) rates.
Results
Among the 4,033 women screened for GDM, 1,249 (31.0%) and 529 (13.1%) had GDM
according to the IADPSG and NICE criteria, respectively. The LGA rate was similar in both
groups. Regardless of the diagnostic criteria, women with GDM had a higher risk of induced
delivery and CSs than controls. In IADPSG-positive non-treated women, offspring’s
BWSDS and CS rate were higher than in controls.
Conclusions
GDM prevalence was 2.4-fold higher according to the IADPSG compared with the NICE cri-
teria but the LGA rate did not differ. BWSDS and CS rate were increased already with mild
untreated hyperglycaemia.
Introduction
The prevalence of gestational diabetes mellitus (GDM) varies, depending on the screening
methods and diagnostic cut-off values applied. For decades, there have been attempts to stan-
dardize the definition, but a consensus has yet to be reached. In 2010, the International Associ-
ation of the Diabetes and Pregnancy Study Group (IADPSG) proposed new diagnostic criteria
based on the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study.[1,2] These
guidelines recommended universal GDM screening using a 2-h 75-g oral glucose tolerance
test (OGTT). The proposed cut-off values represented an odds ratio of 1.75 for
birthweight > 90th centile, cord C-peptide > 90th centile (indicating neonatal hyperinsuline-
mia) and percent body fat > 90th centile. Importantly, for the first time, these diagnostic crite-
ria were based on perinatal outcomes instead of the mother’s subsequent diabetes risk [3].
The diagnostic cut-off values for plasma samples according to the IADPSG criteria
are� 5.1 mmol/L at baseline (fasting sample),� 10.0 mmol/L 1 h and� 8.5 mmol/L 2 h after
a glucose load. These criteria have been widely adopted and are currently recommended by
the World Health Organization and the International Federation of Gynecology and Obstet-
rics (FIGO) [4,5]. However, the National Institutes of Health in the U.S. and the National Insti-
tute for Health and Care Excellence (NICE) in the U.K have not accepted the
recommendation or diagnostic cut-offs because of concerns about a low cost-benefit ratio and
limited evidence of improvements in maternal and neonatal outcomes [6–8]. Thus, at present,
the NICE criteria for the diagnostic cut-offs for fasting and for 2-h postprandial glucose con-
centrations differ significantly from those of the IADPSG (� 5.6 mmol/L whichever� 7.8
mmol/L, respectively), and the 1-h concentration is not included at all [2,7]. Besides these
widely adopted diagnostic criteria, in some countries, including Finland, the diagnostic cut-off
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values for GDM were revised according to American Diabetes Association criteria in 2008
[9,10].
Given the significant differences in the cut-off values for plasma glucose levels, there are
also likely differences in the frequency of GDM diagnoses and perinatal outcomes, depending
on the guidelines applied. The objective of the present study was to evaluate the impact of two
different diagnostic criteria for gestational diabetes mellitus, the IADPSG and the NICE guide-
lines, on the frequency of GDM and perinatal outcomes.
Methods
The data were obtained from the register-based arm of the Finnish Gestational Diabetes Study,
a population-based prospective cohort. [11] The study was initiated in conjunction with the
introduction of new nationwide guidelines for GDM screening, diagnosis and treatment in
Finland. [9,11]
Cohort
The registry data were obtained from the Medical Birth Register (MBR), which includes data
on the course and complications of pregnancy, delivery and perinatal health of the newborn,
as well as International Classification of Diseases (ICD) codes for medical diagnoses of the
mother and child. All pregnancies resulting in a live born infant or stillbirth at� 22 gestational
weeks (gw) or weighting� 500 g are reported in the MBR. These data are linked to the Popula-
tion Register Centre on live births and Statistics Finland on stillbirths and infant deaths. The
coverage of the MBR is practically complete, and the quality of the data is high. [12, 13]
The MBR also includes information on whether an OGTT was performed during preg-
nancy and whether the result was abnormal, but it does not include data on the actual glucose
concentrations. Therefore, we collected numerical OGTT data from all women who delivered
during 2009 in six delivery units in Finland: two tertiary-level (Oulu and Tampere) and four
secondary-level (Lappeenranta, Seinäjoki, Kajaani and Pori) hospitals, each serving a specific
geographical area. These hospitals were chosen as numerical OGTT data were available
through the hospitals’ laboratory information systems. The data on OGTTs from 2008 to 2009
from the laboratory information systems were linked to clinical data from the MBR by person-
nel uninvolved in this study using unique personal identification numbers. After exclusion of
women with pre-pregnancy diabetes and multiple pregnancies, the study population consisted
of 4,033 women, to whom the OGTTs were performed between 24 and 40 gw. (Fig 1).
GDM screening in Finland
The national guidelines published in 2008 introduced comprehensive screening for GDM and
replaced the former risk-factor based screening policy in Finland. According to these guide-
lines, all women, except those with a very low risk, should be screened for GDM using a 75-g
2-h OGTT at 24–28 gw, with the samples obtained at baseline after an overnight fast and 1 and
2 h after the glucose load. High-risk women (i.e. women with prior GDM, a body mass index
[BMI] > 35 kg/m2 or polycystic ovary syndrome with insulin resistance) undergo OGTT
screening for the first time between 12 and 16 gw, and the test is repeated between 24 and 28
gw if the results are normal. Accordingly, women diagnosed with GDM in early pregnancy
based on the OGTT were not included in the present study.
The OGTT is generally performed after a 12-h overnight fast in a laboratory near the
patient’s residence. The samples are drawn from an antecubital vein into fluoride citrate tubes
and analysed within 24 h in a local laboratory using commercial enzymatic assays, with the
assays used varying between laboratories. The national diagnostic cut-offs were based on
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recommendation by the American Diabetes Association at the time of the study:� 5.3 mmol/
L at baseline (fasting sample),� 10.0 mmol/L 1 h and� 8.6 mmol/L 2 h after the glucose load
(S1 Table).9,10 In 2009, which was the first year after the implementation of the new guidelines,
42% of all pregnant women in Finland underwent an OGTT during pregnancy. Thereafter, the
coverage increased significantly, reaching 66% in 2017. According to the national guidelines,
women with one or more abnormal OGTT values receive individualized dietary and lifestyle
counselling and begin glucose self-monitoring. Insulin therapy at the delivery hospital is con-
sidered if self-monitored plasma glucose concentrations repeatedly exceed the target levels
(< 5.5 mmol/L fasting or < 7.8 mmol/L 1 h postprandial), despite the dietary intervention.
The use of oral glycemic agents was occasional and not primarily recommended by the
guidelines.
Covariates
Maternal age was defined at the time of delivery, and parity was defined as the number of pre-
vious deliveries. The BMI was calculated using self-reported height and weight before preg-
nancy (kg/m2), both of which were recorded at the first antenatal visit. Socioeconomic status
was divided into four categories using the occupation reported in the MBR: upper-level
employees, lower-level employees, manual workers and others, such as stay-at-home mothers,
students, pensioners and self-employed individuals. Self-reported smoking status was catego-
rized as non-smokers, those who stopped during the first trimester and those who smoked
after the first trimester, as registered in the MBR.
Outcomes
The main outcome was the frequency of GDM according to the IADPSG and NICE criteria,
and the secondary outcomes were the pregnancy and neonatal outcomes in these groups. Preg-
nancy outcomes included pregnancy induced hypertension (ICD and Related Health Prob-
lems, version 10 [ICD 10] codes O13 and O14 included), induction of labour and delivery
mode (vaginal, vacuum extraction or a caesarean section [CS]). Neonatal outcomes included
birth weight, birth weight standard deviation (SD) scores, birth weight SD scores over 90%,
Fig 1. Flow chart of the study. The diagnosis of GDM was based on one abnormal value in 75g OGTT. IADPSG:
International Association of the Diabetes and Pregnancy Study Group, NICE: The National Institute for Health and
Care Excellence, OGTT: a 2-h 75-g oral glucose tolerance test.
https://doi.org/10.1371/journal.pone.0229496.g001
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small for gestational age (SGA) (i.e. birth weight -2 SD percentile), large for gestational age
(LGA) (i.e. birth weight SD score +2 SD percentile which is the definition used in clinical prac-
tice in Finland; for comparison with other studies, we also report our results with LGA defined
as birth weight SD score over 90th percentile) and gestational age at delivery. The birth weight
SD score is a sex-specific parameter estimating birth weight and length in singletons born at
23–43 gw to primiparous or multiparous mothers according to Finnish standards [14]. Pre-
term delivery was defined as a delivery prior to 37+0 gw. Because the diagnostic criteria for
GDM according to current Finnish care guidelines overlap with those of the IADPSG and
NICE (Table 1), a proportion of women diagnosed with mild GDM by the IADPSG (389
women, 9.6%) or NICE (127 women, 3.1%) criteria remained untreated for GDM during
pregnancy. These groups were evaluated in sub-analyses (Fig 1).
Statistical analyses
All statistical analyses were carried out using the SPSS 21 statistical package. Categorical vari-
ables were reported as frequencies (%), and continuous variables were reported using the
mean (SD). Pearson’s χ2 test was used to compare the difference in proportions in demo-
graphic variables. An independent sample t test was conducted to compare the difference in
the means of demographic data. Differences between each GDM group were tested using Fish-
er’s exact test. Logistic regressions were used to estimate odds ratios (ORs), with their 95%
confidence intervals (CIs) and linear regressions mean differences (with 95% CIs) of outcomes
associated with GDM, respectively, according to the different diagnostic criteria and treatment
status. Logistic and linear regressions were also performed to estimate differences between
each GDM group. The models were adjusted for maternal age, parity and pre-pregnancy BMI.
A two-sided p value of< 0.05 was considered statistically significant.
The study was approved by the regional ethics committee in Northern Ostrobothnia Hospi-
tal District and the National Institute for Health and Welfare. According to Finnish legislation,
information consent form is not needed in Finland, when using anonymous register data only.
Results
OGTT was performed between 24+0 and 40+0 gw (mean 27.5, SD 2.5) in 4,033 women who
delivered in the study hospitals in 2009. Of these women, 1,249 (31.0%) and 529 (13.1%) had
GDM according to the IADPSG and NICE criteria, respectively (Table 2). The control group
Table 1. Diagnostic cut-off values in the 75-g OGTT according to the different diagnostic criteria.
Diagnostic
method
Fasting plasma glucose mmol/L 1-h plasma glucose mmol/L 2-h plasma glucose mmol/L
IADPSG 5.1 10.0 8.5
NICE 5.6 - 7.8
Finnish guidelines� 5.3 10.0 8.6
The OGTT test was interpreted as positive for gestational diabetes if one or more values were equal to or exceeded
their corresponding cut-offs.
�According to Finnish Guidelines, all pregnant women, except those with a very low risk for GDM (primiparous:
age < 25 y, BMI < 25 kg/m2, no family history of diabetes; multiparous: age < 40 y, BMI < 25 kg/m2, no previous
history of foetal macrosomia) are screened for GDM.
OGTT: oral glucose tolerance test
IADPSG: International Association of Diabetes in Pregnancy Study Group
NICE: National Institute for Health and Care Excellence
https://doi.org/10.1371/journal.pone.0229496.t001
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consisted of 2,692 (66.7%) women who were normoglycaemic according to all criteria. Of all
screened women, 860 (21.3%) had GDM according to the prevailing Finnish criteria and were
counselled and medically treated for GDM, if needed. As compared with the controls, women
who had GDM according to either IADPSG or NICE criteria were older and had a higher pre-
pregnancy BMI. Women in the IADPSG GDM group smoked more often and were more
often multiparous when compared with women the NICE GDM group. 57/860 women
received insulin treatment. This represents 6.6% of women who were diagnosed by Finnish
criteria. Of those who met IADPSG criteria, 4.6% received insulin, and of those who met
NICE criteria, 7.2% (Table 3).
When the pregnancy outcomes of the GDM groups were compared with those of the con-
trols, the rates of labour induction, pregnancy induced hypertension was more common and
CSs were higher in both GDM groups, and the gestational age at delivery was lower. In the
NICE group, the proportion of pre-term deliveries was higher than that in the IADPSG group
and in the controls (Table 3). The LGA rate in the two GDM groups did not differ from that in
the controls.
In the IADPSG and NICE groups, 68.9 and 76.0% of women, respectively, fulfilled national
Finnish diagnostic criteria and thus received counselling and treatment. The characteristics of
these pregnancies are presented in the Table 4. Proportion of insulin treated women was
higher in the treated NICE group than in the treated IADPSG group, 9.5% and 6.6%, respec-
tively. The delivery induction and CS rates in both treated GDM groups were higher than
those in the controls. The CS rate and birth weight SD score and large for gestational age as
defined at>90%, were higher in the non-treated IADPSG group than in controls (Table 5,
Figs 2 and 3).
The associations we found were also present after adjustment for maternal age, parity and
pre-pregnancy BMI, although most were slightly attenuated (Table 6).
Table 2. Characteristics of pregnancies with and without GDM, classified according to the different criteria based on the OGTT at 24 to 40 gw.
Characteristics No GDM according to all criteria GDM by IADPSG criteria GDM by NICE criteria
p-value p-value
N (%) 2,692 (66.7) 1,249 (31.0) 529 (13.1)
Maternal age, y 29.4 (5.3) 30.2 (5.6) <0.001 30.3 (5.8) <0.001
Pre-pregnancy BMI, kg/m2 25.5 (4.3) 27.2 (5.1) <0.001 27.0 (5.1) <0.001
Primiparity 1,333 (49.5) 560 (44.8) 0.006 259 (49.0) 0.815
Smoking
No 2,265 (87.5) 1,017 (84.5) 0.011 435 (85.0) 0.120
Quit in the first trimester 109 (4.2) 59 (4.9) 0.336 26 (5.1) 0.379
Continued after the first trimester 215 (8.3) 128 (10.6) 0.020 51 (10.0) 0.221
Socioeconomic status
Upper-white collar workera 470 (21.6) 190 (19.2) 0.112 74 (17.6) 0.063
Lower-white collar workerb 889 (40.9) 421 (42.5) 0.417 181 (43.1) 0.413
Blue-collar workerc 358 (16.5) 184 (18.6) 0.151 83 (19.8) 0.102
Otherd 454 (20.9) 196 (19.8) 0.464 82 (19.5) 0.520
Data are n (%) or mean (SD).
aAdministrative, managerial, professional and related occupations.
bAdministrative and clerical occupations.
cManual labourer.
dStudents, pensioners, self-employed and others.
BMI: body mass index
https://doi.org/10.1371/journal.pone.0229496.t002
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Discussion
Main findings
Among all the women who underwent OGTT, the proportion of GDM was 2.4-fold higher
when diagnosed by the IADPSG (31.0%) criteria as compared with when diagnosed by the
NICE criteria (13.1%). The proportion of LGA infants was similar in both the GDM groups
and controls, which may reflect successful counselling and treatment. While the diagnostic
cut-offs partly overlapped, we had also a possibility to evaluate a subgroup without treatment.
Mild untreated hyperglycaemia was associated with an increased CS rate and higher birth
weights, as found in the HAPO study and some recent studies [15,16].
The main short-term goal of GDM management is to prevent macrosomia. Large random-
ized studies have demonstrated that achievement of euglycaemia leads to better perinatal out-
comes such as lower birth weight and lower macrosomia rate already in mild cases of GDM.
[17, 18] In our, and also some previous studies, GDM treatment can be considered successful,
as neither birth weight nor perinatal outcomes differed between the controls and GDM groups
[19]. The success of GDM treatment may also be attributed to the widespread adoption of
national guidelines in Finland and the existence of good co-operation between primary and
special health care services. The rates of induced deliveries and CSs were higher in both the
treated GDM groups, irrespective of which diagnostic criteria were applied. It may be sup-
posed that the diagnosis of GDM itself at some extent predispose women to those interven-
tions. On the other hand, the birth weight SD score and CS rate showed an increasing
tendency in cases with mild hyperglycaemia, without a diagnosis of GDM. This finding is in
Table 3. Outcomes of pregnancies with GDM classified according to the different criteria based on the OGTT at 24 to 40 gw.
Characteristics No GDM according to all criteria IADPSG NICE
N (%/SD) p-value� N (%/SD) p-value�
N (%) 2,692 (66.7) 1,249 (31.0) 529 (13.1)
Gestational age at delivery, wk 39.9 (1.6) 39.6 (1.8) <0.001 39.4 (2.0) <0.001
Birth weight, g (SD) 3,571 (523.7) 3,558 (557.5) 0.511 3490 (620.0) 0.002
Birth weight, SD score -0.05 (1.0) 0.04 (1.0) 0.012 0.01 (1.1) 0.293
Small for gestational age, <-2 SD 76 (2.8) 32 (2.6) 0.640 15 (2.8) 0.987
Large for gestational age, >+2SD 72 (2.7) 36 (2.9) 0.710 21 (4.0) 0.104
Large for gestational age, >90% 250 (9.3) 141 (11.3) 0.050 65 (12.3) 0.034
Induced delivery 414 (15.4) 259 (20.7) <0.001 121 (22.9) <0.001
Pre-term birth 22 (0.8) 18 (1.4) 0.069 11 (2.1) 0.008
Insulin treatment 0 57 (4.6) <0.001 38 (7.2) <0.001
Pregnancy induced hypertension� 165 (6.1) 100 (8.0) 0.029 48 (9.1) 0.013
Type of delivery
Vaginal non-instrumental 2,048 (76.1) 894 (71.6) 0.003 372 (70.3) 0.005
Instrumental 242 (9.0) 95 (7.6) 0.148 40 (7.6) 0.288
Caesarean section 402 (14.9) 260 (20.8) <0.001 117 (22.1) <0.001
Hospital stay of mother in days 3.1 (1.4) 3.2 (1.4) 0.001 3.4 (1.5) <0.001
Hospital stay of offspring in days 3.1 (2.7) 3.3 (1.9) 0.025 3.4 (2.5) 0.017
Data are n (%) or mean (SD)
�p-value between GDM-group and controls.
��International classification of diseases ICD-10: O13, O14
https://doi.org/10.1371/journal.pone.0229496.t003
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accordance with the results of the HAPO study, which reported a linear increase in adverse
perinatal outcomes without specific cut-offs. [1]
Different diagnostic cut-offs in GDM screening might be expected to result in different
maternal profiles: The IADPSG criteria emphasize the importance of fasting glucose, whereas
the NICE guidelines focus on low 2-h postprandial glucose concentration. As compared with
the control group, women in the IADPSG group with lower fasting glucose concentrations
were more often multiparous and smokers. In the NICE GDM group, the proportion of insu-
lin-treated mothers (7.2%) was higher than that in the IADPSG GDM group (4.6%), which
may partly indicate the different grades of severity of GDM in the two groups. Between the
treated groups, the difference between NICE and IADPSG groups was even higher, 9.5% vs
6.6%. Pre-term birth was most common in the NICE groups, regardless of treatment. The rea-
son remained unclear.
In multivariate logistic and linear regression analyses the results were adjusted with mater-
nal age, parity and pre-pregnancy BMI, which are independent risk factors for adverse preg-
nancy outcome. In our study, the significance of the results remained despite adjustment with
these factors.
Table 4. Characteristics of pregnancies with GDM classified according to the different GDM diagnostic criteria, with or without treatment.
Characteristics Control group IADPSG p-value�� NICE p-value��
Treated Non-treated Treated Non-treated
p-value� p-value� p-value� p-value�





Maternal age, y 29.4 (5.3) 30.2 (5.6) <0.001 30.0 (5.7) 0.033 0.462 30.4 (5.9) 0.001 30.0 (5.5) 0.223 0.498
Pre-pregnancy BMI, kg/m2 25.5 (4.3) 27.4 (5.2) <0.001 26.9 (4.7) <0.001 0.150 27.4 (5.1) <0.001 25.4 (4.6) 0.799 <0.001






0.573 66 (52.0) 0.589 0.437
Smoking






0.044 109 (88.6) 0.710 0.193
Quit in the first trimester 109 (4.2) 39 (4.7) 0.521 20 (5.3) 0.347 0.692 19 (4.9) 0.541 7 (5.7) 0.428 0.722
Continued after the first
trimester
215 (8.3) 94 (11.4) 0.007 34 (8.9) 0.673 0.198 44 (11.3) 0.050 7 (5.7) 0.302 0.070
Socioeconomic status
Upper-white collar workera 470 (21.6) 125
(18.4)
0.067 65 (20.9) 0.764 0.350 62 (19.5) 0.382 12 (11.8) 0.017 0.074






0.252 40 (39.2) 0.728 0.363
Blue-collar workerc 358 (16.5) 136
(20.0)
0.035 48 (15.4) 0.638 0.086 56 (17.6) 0.616 27 (26.5) 0.009 0.051
Otherd 454 (20.9) 125
(18.4)
0.152 71 (22.8) 0.439 0.103 59 (18.6) 0.332 23 (22.5) 0.692 0.376
Data are n (%) or mean (SD).
�p-value between GDM-group and controls.
��p-value between treated/non-treated.
aAdministrative, managerial, professional and related occupations.
b Administrative and clerical occupations.
cManual labourer.
dStudents, pensioners, self-employed and others.
BMI: body mass index
https://doi.org/10.1371/journal.pone.0229496.t004
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Table 5. Outcomes of pregnancies with GDM classified according to the different GDM diagnostic criteria, with or without treatment.
Characteristics No GDM IADPSG p-value�� NICE p-value��
Treated Non-treated Treated Non-treated
p-value� p-value� p-value� p-value�
N 2,692
(66.7)
860 (21.3) 389 (9.6) 402 (10.0) 127 (3.1)
Gestational age at delivery, wk 39.9 (1.6) 39.5 (1.9) <0.001 39.9 (1.6) 0.377 0.001 39.3 (2.0) <0.001 39.5 (2.0) 0.002 0.339






0.013 3,463 (610) 0.025 0.565
Birth weight, SD score -0.046 (1.0) 0.017 (1.0) 0.120 0.099 (1.1) 0.012 0.208 0.037 (1.2) 0.176 -0.074
(1.1)
0.768 0.317
Small for gestational age, <-2 SD 76 (2.8) 20 (2.3) 0.433 12 (3.1) 0.772 0.432 10 (2.5) 0.703 5 (3.9) 0.463 0.391
Large for gestational age, >+2 SD 72 (2.7) 23 (2.7) 1.000 13 (3.3) 0.453 0.514 17 (4.2) 0.082 4 (3.1) 0.747 0.587
Large for gestational age, >90% 250 (9.3) 88 (10.2) 0.411 53 (13.6) 0.007 0.079 49 (12.2) 0.066 16 (12.6) 0.212 0.903
Induced delivery 414 (15.4) 192 (22.3) <0.001 67 (17.2) 0.349 0.039 94 (23.4) <0.001 27 (21.3) 0.075 0.619
Preterm birth 22 (0.8) 13 (1.5) 0.073 5 (1.3) 0.354 0.756 7 (1.7) 0.073 4 (3.1) 0.007 0.332
Insulin treatment 0 57 (6.6) <0.001 0 <0.001 38 (9.5) <0.001 0 <0.001
Pregnancy induced
hypertension���




616 (71.6) 0.009 278 (71.5) 0.048 0.953 278 (69.2) 0.003 94 (74.0) 0.595 0.296
Instrumental 242 (9.0) 65 (7.6) 0.193 30 (7.7) 0.406 0.924 32 (8.0) 0.498 8 (6.3) 0.297 0.537
Caesarean section 402 (14.9) 179 (20.8) <0.001 81 (20.8) 0.003 0.997 92 (22.9) <0.001 25 (19.7) 0.144 0.447
Hospital stay of mother in days 3.1 (1.4) 3.2 (1.4) 0.001 3.2 (1.3) 0.196 0.237 3.4 (1.5) <0.001 3.3 (1.3) 0.033 0.615
Hospital stay of offspring in days 3.1 (2.7) 3.4 (2.1) 0.021 3.2 (1.3) 0.253 0.157 3.5 (2.8) 0.008 3.2 (1.3) 0.718 0.058
Data are n (%) or mean (SD).
�p-value between GDM-group and controls.
��p-value between treated/non-treated.
���International classification of diseases ICD-10: O13, O14
https://doi.org/10.1371/journal.pone.0229496.t005
Fig 2. Association between caesarean section and GDM groups identified by different diagnostic criteria. Logistic
regression analyses were used to estimate unadjusted and adjusted (for maternal age, parity and pre-pregnancy body
mass index) odds ratios (OR) with 95% CI, whiskers expressing the 5th and 95th percentiles. IADPSG: International
Association of the Diabetes and Pregnancy Study Group, NICE: The National Institute for Health and Care Excellence.
https://doi.org/10.1371/journal.pone.0229496.g002
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Strengths and limitations
The strengths of this study are the large cohort and ability to evaluate the significance of
numerical OGTT values. The quality and completeness of the MBR are high, and the current
data cover geographically diverse regions of Finland. As a limitation, during the study period
the coverage of new nationwide GDM screening was rather low (42%) while the new screening
protocol had been launched just a year earlier and therefore not fully implemented. Control
population consisted of those with known OGTT results. Thus, non-screened women with the
lowest risk of GDM were not included in this study, but this is not a bias because we classified
women with known results of OGTT, not with the risk of GDM. We speculate that those who
did not undergo OGTT and the undiagnosed GDM mothers would on average represent a
Fig 3. Association between large for gestational age, defined as birth weight>90th percentile, in GDM groups
identified by different diagnostic criteria. Logistic regression analyses were used to estimate unadjusted and adjusted
(for maternal age, parity and pre-pregnancy body mass index) odds ratios (OR) with 95% CI, whiskers expressing the
5th and 95th percentiles. IADPSG: International Association of the Diabetes and Pregnancy Study Group, NICE: The
National Institute for Health and Care Excellence.
https://doi.org/10.1371/journal.pone.0229496.g003
Table 6. Multivariate logistic and linear regression analysis of perinatal and neonatal outcomes in patients according to the application of the different GDM diag-
nostic methods.
Non-treated IADPSG Treated IADPSG Non-treated NICE Treated NICE
Outcome OR aOR OR aOR OR aOR OR aOR
































































































Data are OR (95% CI), aOR = OR adjusted for maternal age, parity and pre-pregnancy BMI. Exception: Mean difference (95% CI = confidential interval) for birth
weight SD score.
https://doi.org/10.1371/journal.pone.0229496.t006
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milder end of the GDM spectrum and the present study may underestimate their proportion.
In order to exclude possible overt or pre-pregnancy diabetes, only women with OGTT per-
formed after recommended screening time point (> 24 gestational weeks) were included. The
study also had limited power to assess rare perinatal outcomes.
Conclusion
In conclusion, there was a significant difference in the prevalence of GDM diagnosed by the
different criteria, but the pregnancy outcomes were similar using the two diagnostic methods:
the use of NICE criteria only would have identified less GDM women than the use of IADPSG
criteria, but would also likely to have left unidentified a group of GDM women who had a sim-
ilar proportion of these pregnancy outcomes and might have benefited from GDM treatment.
The main aim of GDM treatment, prevention of macrosomia, was attained by both criteria.
The similarity in pregnancy outcomes in GDM mothers and normoglycaemic controls may
reflect successful, uniform counselling and treatment and well-organized maternal health care.
Mild untreated hyperglycaemia was associated with an increased CS rate and higher birth
weights, as reported by the HAPO and some recent studies. [1,20] In the future, studies are
needed to determine how these different diagnostic methods will predict a woman´s subse-
quent risk for type 2 diabetes and other long-term outcomes.
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